This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Vivus: Prepping for Thursday's FDA Panel

BOSTON ( TheStreet) -- Some thoughts, comments and notes in advance of tomorrow's FDA advisory panel meeting to review Vivus' (VVUS) weight-loss drug Qnexa:

I was asked on Twitter yesterday for my prediction on the outcome of the panel vote on Qnexa. I believe the panel will vote to recommend Qnexa's approval. I'm forecasting a mixed/close vote. This will not be a landslide victory for the drug.

I conducted a quick poll of 20 sources last night -- biotech hedge fund managers, buyside analysts and healthcare brokers -- asking them the same question. The result: 17 votes predicting a positive Qnexa vote, three votes believing the panel will go against the drug.

I'm live blogging Thursday's FDA panel in its entirety. I'll kick things off around 7:45 am EDT, the panel gets underway at 8 am and should wrap up in mid-to-late afternoon. Sign up below if you want an email reminder.

Judging by the rise in the stock prices of Arena Pharmaceuticals (ARNA) and Orexigen Therapeutics (OREX), what's good for Vivus might also be good for its obesity drug competitors. That may change depending on the discussion and debate at tomorrow's panel meeting.

Trading in Vivus shares will be halted tomorrow. That leaves traders to play with Arena and Orexigen. It will be interesting to see what level of volatility we get in those stocks as the panel progresses.

I haven't spoken to Vivus in front of tomorrow's panel but the company looks well prepared to tackle the safety concerns and questions that have cropped about Qnexa, judging by the printed agenda. Vivus has five speakers presenting Qnexa data to the advisory panel, including outside experts to discuss neuro-psychiatric safety, pregnancy risks, and risk management plans, including a proposal for a post-approval study to assess cardiovascular outcomes in patients treated with Qnexa.

These safety-related issues are going to be the hot-button topics tomorrow, so Vivus looks ready to make its case. I've covered a lot of FDA advisory panels in my days, and I'm constantly surprised to see how some companies enter this treacherous territory totally unprepared. I don't expect Vivus to fall into that category tomorrow.

I was emailed some commentary from a biotech stock newsletter that's short Vivus. The newsletter said, in part, that the FDA's relatively benign review of Qnexa posted online Tuesday was a bad sign because it gave the agency free reign to carpet bomb the drug with criticism at Thursday's panel.

I disagree. I find that the FDA is never shy about voicing a negative opinion in briefing documents when the agency doesn't like something. What surprised me most about the FDA's Qnexa review was the lack of a smoking gun. I kept waiting for that devastating analysis or piece of negative data that we didn't know about. For the most part, nothing of the sort was in the FDA's review. That's why Vivus shares have been up for the past two days.

I don't anticipate much debate about Qnexa's efficacy. The pill helps obese patients lose weight. Most of the contentious discussion will be about the drug's safety. I'm probably most interested in hearing the discussion on pregnancy risk since this poses a potential problem if/when Qnexa is approved and marketed.

From the FDA's briefing documents, the agency seems very concerned about the number of women in the Qnexa trials who got pregnant despite a requirement that they be using birth control. The two individual components of Qnexa -- phentermine and topiramate -- both carry Category C pregnancy risks, which tells doctors to treat pregnant patients with the drugs if the benefits outweigh the risks.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs